Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh
Executive Summary
Co-development deal worth $265m in near-term cash will allow Akebia to tap into Otsuka's established kidney disease infrastructure, while holding the reins on key aspects of commercialization.
You may also be interested in...
Akebia's Vadadustat Misses In Non-Dialysis CKD, But Filings Still Planned For 2021
HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.
Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.
Positive Results Move Anemia Contender Enarodustat Towards First Filing
Japanese firms unveil pivotal top-line results that pave way for first filing of novel anemia therapy within new class of agents, but competition is high and timings remain unclear.